PATHOPHYSIOLOGICAL SUBSTANTIATION OF THE USE OF A NEW DRUG BASED ON G. LUCIDUM AND ALKHADIA IN THE TREATMENT OF CORONAVIRUS INFECTION CAUSED BY SARS COV-2
No. 3 (2022), Articles
No. 3 (2022)

PATHOPHYSIOLOGICAL SUBSTANTIATION OF THE USE OF A NEW DRUG BASED ON G. LUCIDUM AND ALKHADIA IN THE TREATMENT OF CORONAVIRUS INFECTION CAUSED BY SARS COV-2

Articles
Published 2022-10-03
Pulat M. Abilov
Bakhtiyor U. Iriskulov
Zukhra N. Boboeva
PDF

Keywords

coronavirus infection, pathogenesis, acute respiratory syndrome, G. lucidum, Alkhadaya

How to Cite

Pulat M. Abilov, Bakhtiyor U. Iriskulov, & Zukhra N. Boboeva. (2022). PATHOPHYSIOLOGICAL SUBSTANTIATION OF THE USE OF A NEW DRUG BASED ON G. LUCIDUM AND ALKHADIA IN THE TREATMENT OF CORONAVIRUS INFECTION CAUSED BY SARS COV-2. Central Asian Journal of Medicine, (3), 36-44. Retrieved from https://journals.tma.uz/index.php/cajm/article/view/500
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

The current outbreak of coronavirus disease (COVID-19) is a global emergency as its rapid spread and high mortality rate have caused severe disruption. The number of people infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, is rapidly increasing worldwide. Patients with COVID-19 may develop pneumonia, severe symptoms of acute respiratory distress syndrome (ARDS) and multiple organ failure.

PDF